Utsumi Ryuichi, Terai Hideki, Arai Tetsuya, Iwabuchi Yu, Akiyama Mitsuhiro, Nukaga Shigenari, Ohgino Keiko, Kabata Hiroki, Chubachi Shotaro, Yasuda Hiroyuki, Fukunaga Koichi
Division of Pulmonary Medicine, Department of Internal Medicine Keio University School of Medicine Tokyo Japan.
Keio Cancer Center Keio University School of Medicine Tokyo Japan.
Respirol Case Rep. 2025 Jun 25;13(6):e70242. doi: 10.1002/rcr2.70242. eCollection 2025 Jun.
Immune-checkpoint inhibitors (ICIs) have become one of the main strategies for advanced cancers. ICIs are associated with many immune side effects, called immune-related adverse events (irAEs). Since irAE has various variations, it is important to carefully examine each individual case that develops irAE. We experienced a case of polymyalgia rheumatica (PMR)-like irAE after three courses of administration of Ipilimumab and Nivolumab for stage IV lung adenocarcinoma. We also confirmed that the activity of this irAE was detectable on the PET-CT scan performed to assess lung cancer progression. Given the limited reports of PMR-like irAE occurring after treatment with two immune checkpoint inhibitors, we present this case along with a review of the literature.
免疫检查点抑制剂（ICIs）已成为晚期癌症的主要治疗策略之一。ICIs与许多免疫副作用相关，称为免疫相关不良事件（irAEs）。由于irAE有多种表现形式，仔细检查每一例发生irAE的个体病例很重要。我们遇到一例在接受三疗程伊匹木单抗和纳武单抗治疗IV期肺腺癌后出现类风湿性多肌痛（PMR）样irAE的病例。我们还证实，在为评估肺癌进展而进行的PET-CT扫描上可检测到这种irAE的活性。鉴于关于两种免疫检查点抑制剂治疗后发生类PMR样irAE的报道有限，我们在此展示该病例并对文献进行综述。
